Daftary A, Chiao J P, Caritis S N
Department of Obstetrics and Gynecology, Travis Air Force Base, California, USA.
J Matern Fetal Med. 1996 May-Jun;5(3):155-60. doi: 10.1002/(SICI)1520-6661(199605/06)5:3<155::AID-MFM11>3.0.CO;2-I.
The purpose of this study was to determine in vivo the dose response relationship between beta-adrenergic receptor (BAR) agonist concentration and various elements of the BAR cascade: receptor density, hormone-stimulable adenylyl cyclase activity, and contraction inhibition. A previously described, chronically-catheterized ovine model was used. Ritodrine was infused continuously over 24 h in 22 mixed-breed sheep. Each animal received a single, constant infusion rate. Myometrial biopsies were obtained before and after the drug infusions. BAR density was determined using tritiated dihydroalprenolol. Adenylyl cyclase activity was determined using the Gilman competitive protein-binding assay. Intermittent oxytocin boluses were given into the maternal aorta and contractile response was determined. Infusion rates of 0.06-4.0 micrograms/kg/min yielded steady-state ritodrine serum concentrations of 5-168 ng/ml. No significant correlation was found between the ritodrine concentration and the magnitude of decrease in BAR density. Significant correlations existed, however, between the ritodrine concentration and both the magnitude of decrease in adenylyl cyclase activity and the loss of contraction inhibition. There was no correlation noted between the BAR cascade alterations and the loss of contraction inhibition. Despite significant reductions in receptor density (down regulation) and dose-related reductions in hormone-stimulable adenylyl cyclase activity (uncoupling), ritodrine at low concentrations was still able to inhibit oxytocin-induced contractions, i.e., tachyphylaxis did not occur. Tachyphylaxis appeared to correlate only with the serum ritodrine concentration. Hence, alterations in the BAR cascade do not necessarily equate with a loss of end-organ response (tachyphylaxis). Previous concepts based on in vitro studies about the interaction of the BAR agonist with its receptor, the subsequent generation of intracellular messengers, and the resultant end-organ response may not apply in the intact animal.
本研究的目的是在体内确定β-肾上腺素能受体(BAR)激动剂浓度与BAR级联反应的各种要素之间的剂量反应关系:受体密度、激素刺激的腺苷酸环化酶活性和收缩抑制。使用了先前描述的慢性插管绵羊模型。在22只杂种绵羊中连续24小时输注利托君。每只动物接受单一、恒定的输注速率。在药物输注前后获取子宫肌层活检样本。使用氚标记的二氢阿普洛尔测定BAR密度。使用吉尔曼竞争性蛋白结合测定法测定腺苷酸环化酶活性。向母体主动脉内间歇性推注催产素,并测定收缩反应。0.06 - 4.0微克/千克/分钟的输注速率产生的稳态利托君血清浓度为5 - 168纳克/毫升。未发现利托君浓度与BAR密度降低幅度之间存在显著相关性。然而,利托君浓度与腺苷酸环化酶活性降低幅度和收缩抑制丧失之间均存在显著相关性。未观察到BAR级联反应改变与收缩抑制丧失之间存在相关性。尽管受体密度显著降低(下调)且激素刺激的腺苷酸环化酶活性存在剂量相关的降低(解偶联),但低浓度的利托君仍能够抑制催产素诱导的收缩,即未出现快速耐受。快速耐受似乎仅与血清利托君浓度相关。因此,BAR级联反应的改变不一定等同于终末器官反应的丧失(快速耐受)。基于体外研究得出的关于BAR激动剂与其受体相互作用、随后细胞内信使的产生以及最终终末器官反应的先前概念可能不适用于完整动物。